Krsnaa Diagnostics Reports Strong Financial Performance in Q2 FY25, Potential Investment Opportunity in Healthcare Industry

Oct 25 2024 11:02 PM IST
share
Share Via
Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, has reported a significant improvement in its financial performance for the quarter ending September 2024. With the highest net sales, operating profit, and PBT in the last five quarters, the company shows positive near-term trends and potential for investors.

Krsnaa Diagnostics, a smallcap company in the hospital and healthcare services industry, has recently declared its financial results for the quarter ending September 2024. The company has received a ‘Buy’ call from MarketsMOJO, indicating positive prospects for investors.

In the last three months, Krsnaa Diagnostics has shown a significant improvement in its financial performance, with a score of 15 compared to -7 in the previous quarter. This is a result of the company’s highest net sales of Rs 186.34 crore, which has been growing consistently in the last five quarters. The near-term sales trend is also very positive.


The company’s profit before tax less other income (PBT) has also seen a growth of 50.2% over the average PBT of the previous four quarters, reaching Rs 20.81 crore. The operating profit (PBDIT) has also been the highest in the last five quarters at Rs 49.40 crore, indicating a positive trend in the near term. The operating profit margin has also improved to 26.51%, showcasing the company’s efficiency.


Krsnaa Diagnostics has also recorded its highest PBT of Rs 20.81 crore and PAT of Rs 19.60 crore in the last five quarters. The near-term trend for both PBT and PAT is positive, with a growth of 30.4% over the average PAT of the previous four quarters. This signifies the company’s increasing profitability and ability to generate higher earnings for its shareholders.


However, the company’s interest cost has also seen a significant increase of 107.52% over the preceding nine months period, indicating a rise in borrowings. This is an area that the company needs to address in order to maintain its positive financial performance.


Overall, Krsnaa Diagnostics has shown a strong financial performance in the quarter ending September 2024, with positive trends in sales, PBT, PAT, and EPS. Investors can consider this smallcap company as a potential investment opportunity in the hospital and healthcare services industry.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News